{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:57:37Z","timestamp":1781053057313,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1038\/ncprheum0139","type":"journal-article","created":{"date-parts":[[2006,5,16]],"date-time":"2006-05-16T16:49:23Z","timestamp":1147798163000},"page":"192-200","source":"Crossref","is-referenced-by-count":29,"title":["Therapeutics of Wegener's granulomatosis"],"prefix":"10.1038","volume":"2","author":[{"given":"Peter K","family":"Wung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncprheum0139_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/art.1780390112","volume":"39","author":"MF Cotch","year":"1996","unstructured":"Cotch MF et al. (1996) The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39: 87\u201392","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS et al. (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488\u2013498","journal-title":"Ann Intern Med"},{"key":"BFncprheum0139_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","volume":"43","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller E et al. (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43: 1021\u20131032","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR4","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/art.11075","volume":"48","author":"JH Stone","year":"2003","unstructured":"Stone JH (2003) Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 48: 2299\u20132309","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR5","doi-asserted-by":"crossref","unstructured":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351\u2013361","DOI":"10.1056\/NEJMoa041884"},{"key":"BFncprheum0139_CR6","first-page":"455","volume":"42","author":"H Klinger","year":"1931","unstructured":"Klinger H (1931) Grenzformen der periarteritis nodosa [German]. Frankfurt Z Pathol 42: 455\u2013480","journal-title":"Frankfurt Z Pathol"},{"key":"BFncprheum0139_CR7","first-page":"202","volume":"29","author":"F Wegener","year":"1936","unstructured":"Wegener F (1936) \u00dcber generalisierte, septische gefasserkrankungen [German]. Verh Dtsch Ges Pathol 29: 202\u2013210","journal-title":"Verh Dtsch Ges Pathol"},{"key":"BFncprheum0139_CR8","first-page":"36","volume":"36","author":"F Wegener","year":"1939","unstructured":"Wegener F (1939) \u00dcber eine eigenartige rhinogene granulomatose mit besonderer beteiligung des Arteriensystems und der Nieren [German]. Beitr Pathol Anat Allg Pathol 36: 36\u201368","journal-title":"Beitr Pathol Anat Allg Pathol"},{"key":"BFncprheum0139_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","volume":"34","author":"EW Walton","year":"1958","unstructured":"Walton EW (1958) Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 34: 265\u2013270","journal-title":"Br Med J"},{"key":"BFncprheum0139_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","volume":"67","author":"D Hollander","year":"1967","unstructured":"Hollander D and Manning RT (1967) The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 67: 393\u2013398","journal-title":"Ann Intern Med"},{"key":"BFncprheum0139_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJM197112302852701","volume":"285","author":"AS Fauci","year":"1971","unstructured":"Fauci AS et al. (1971) Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 285: 1493\u20131496","journal-title":"N Engl J Med"},{"key":"BFncprheum0139_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/art.1780351113","volume":"35","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS et al. (1992) The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35: 1322\u20131329","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR13","doi-asserted-by":"crossref","unstructured":"WGET Research Group (2002) Design of the Wegener's granulomatosis etanercept trial (WGET). Control Clin Trials 23: 450\u2013468","DOI":"10.1016\/S0197-2456(02)00209-X"},{"key":"BFncprheum0139_CR14","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/art.21117","volume":"52","author":"P Seo","year":"2005","unstructured":"Seo P et al. (2005) Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's granulomatosis etanercept trial (WGET). Arthritis Rheum 52: 2168\u20132178","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR15","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","volume":"41","author":"M Haubitz","year":"1998","unstructured":"Haubitz M et al. (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41: 1835\u20131844","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR16","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin L et al. (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40: 2187\u20132198","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR17","first-page":"195","volume":"28","author":"K De Groot","year":"2005","unstructured":"De Groot K et al. (2005) Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis. Kidney Blood Press Res 28: 195","journal-title":"Kidney Blood Press Res"},{"key":"BFncprheum0139_CR18","first-page":"492","volume":"25","author":"K De Groot","year":"1998","unstructured":"De Groot K et al. (1998) Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 25: 492\u2013495","journal-title":"J Rheumatol"},{"key":"BFncprheum0139_CR19","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R","volume":"43","author":"CA Langford","year":"2000","unstructured":"Langford CA et al. (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43: 1836\u20131840","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/art.1780380505","volume":"38","author":"MC Sneller","year":"1995","unstructured":"Sneller MC et al. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608\u2013613","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461\u20132469","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","volume":"17","author":"ON Goek","year":"2005","unstructured":"Goek ON and Stone JH (2005) Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol 17: 257\u2013264","journal-title":"Curr Opin Rheumatol"},{"key":"BFncprheum0139_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0002-9343(03)00077-9","volume":"114","author":"CA Langford","year":"2003","unstructured":"Langford CA et al. (2003) Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114: 463\u2013469","journal-title":"Am J Med"},{"key":"BFncprheum0139_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.10459","volume":"47","author":"E Reinhold-Keller","year":"2002","unstructured":"Reinhold-Keller E et al. (2002) High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47: 326\u2013332","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36\u201344","journal-title":"N Engl J Med"},{"key":"BFncprheum0139_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00000441-200101000-00009","volume":"321","author":"DA Russian","year":"2001","unstructured":"Russian DA and Levine SJ (2001) Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci 321: 56\u201365","journal-title":"Am J Med Sci"},{"key":"BFncprheum0139_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH and Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71: 5\u201313","journal-title":"Mayo Clin Proc"},{"key":"BFncprheum0139_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s150100070041","volume":"28","author":"T Gluck","year":"2000","unstructured":"Gluck T et al. (2000) Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 28: 227\u2013230","journal-title":"Infection"},{"key":"BFncprheum0139_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/milmed\/161.1.58","volume":"161","author":"S Krebs","year":"1996","unstructured":"Krebs S and Gibbons RB (1996) Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med 161: 58\u201360","journal-title":"Mil Med"},{"key":"BFncprheum0139_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","volume":"339","author":"WM El-Sadr","year":"1998","unstructured":"El-Sadr WM et al. (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 339: 1889\u20131895","journal-title":"N Engl J Med"},{"key":"BFncprheum0139_CR31","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1200\/JCO.1991.9.11.2016","volume":"9","author":"JD Shepherd","year":"1991","unstructured":"Shepherd JD et al. (1991) Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9: 2016\u20132020","journal-title":"J Clin Oncol"},{"key":"BFncprheum0139_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/bjc.1984.252","volume":"50","author":"JM Hows","year":"1984","unstructured":"Hows JM et al. (1984) Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in bone marrow transplantation: a prospective randomised study. Br J Cancer 50: 753\u2013756","journal-title":"Br J Cancer"},{"key":"BFncprheum0139_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/ard.2004.023937","volume":"63","author":"B Hellmich","year":"2004","unstructured":"Hellmich B et al. (2004) Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 63: 1183\u20131185","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0139_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11926-004-0085-1","volume":"6","author":"J Compston","year":"2004","unstructured":"Compston J (2004) US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep 6: 66\u201369","journal-title":"Curr Rheumatol Rep"},{"key":"BFncprheum0139_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2796.2005.01467.x","volume":"257","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P et al. (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257: 374\u2013384","journal-title":"J Intern Med"},{"key":"BFncprheum0139_CR36","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","volume":"293","author":"HA Bischoff-Ferrari","year":"2005","unstructured":"Bischoff-Ferrari HA et al. (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293: 2257\u20132264","journal-title":"JAMA"},{"key":"BFncprheum0139_CR37","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","volume":"291","author":"E Banks","year":"2004","unstructured":"Banks E et al. (2004) Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291: 2212\u20132220","journal-title":"JAMA"},{"key":"BFncprheum0139_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA et al. (1996) Trimethoprim\u2013sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 335: 16\u201320","journal-title":"N Engl J Med"},{"key":"BFncprheum0139_CR39","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","volume":"42","author":"PJ Klemmer","year":"2003","unstructured":"Klemmer PJ et al. (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42: 1149\u20131153","journal-title":"Am J Kidney Dis"},{"key":"BFncprheum0139_CR40","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","volume":"35","author":"DR Jayne","year":"1996","unstructured":"Jayne DR and Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35: 1150\u20131153","journal-title":"Br J Rheumatol"},{"key":"BFncprheum0139_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DR Jayne","year":"2000","unstructured":"Jayne DR et al. (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433\u2013439","journal-title":"QJM"},{"key":"BFncprheum0139_CR42","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1523-1755.2004.00534.x","volume":"65","author":"WH Schmitt","year":"2004","unstructured":"Schmitt WH et al. (2004) Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65: 1440\u20131448","journal-title":"Kidney Int"},{"key":"BFncprheum0139_CR43","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/S0041-1345(01)01948-0","volume":"33","author":"FJ van der Woude","year":"2001","unstructured":"van der Woude FJ et al. (2001) Immunosuppression in ANCA-associated vasculitis. Transplant Proc 33: 2225\u20132226","journal-title":"Transplant Proc"},{"key":"BFncprheum0139_CR44","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/01.CIR.0000124720.18538.DD","volume":"109","author":"AD Booth","year":"2004","unstructured":"Booth AD et al. (2004) Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109: 1718\u20131723","journal-title":"Circulation"},{"key":"BFncprheum0139_CR45","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","volume":"41","author":"P Bartolucci","year":"2002","unstructured":"Bartolucci P et al. (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxf) 41: 1126\u20131132","journal-title":"Rheumatology (Oxf)"},{"key":"BFncprheum0139_CR46","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","volume":"41","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht P et al. (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxf) 41: 1303\u20131307","journal-title":"Rheumatology (Oxf)"},{"key":"BFncprheum0139_CR47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh KA et al. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262\u2013268","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","volume":"43","author":"C Metzler","year":"2004","unstructured":"Metzler C et al. (2004) Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxf) 43: 315\u2013320","journal-title":"Rheumatology (Oxf)"},{"key":"BFncprheum0139_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/art.20240","volume":"51","author":"CA Langford","year":"2004","unstructured":"Langford CA et al. (2004) Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 51: 278\u2013283","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0139_CR50","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.V1091965","volume":"10","author":"R Nowack","year":"1999","unstructured":"Nowack R et al. (1999) Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10: 1965\u20131971","journal-title":"J Am Soc Nephrol"},{"key":"BFncprheum0139_CR51","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.4049\/jimmunol.169.9.4982","volume":"169","author":"H Holcombe","year":"2002","unstructured":"Holcombe H et al. (2002) The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation. J Immunol 169: 4982\u20134989","journal-title":"J Immunol"},{"key":"BFncprheum0139_CR52","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1084\/jem.183.6.2427","volume":"183","author":"B Wang","year":"1996","unstructured":"Wang B et al. (1996) The immunosuppressant 15-deoxyspergualin reveals commonality between preT and preB cell differentiation. J Exp Med 183: 2427\u20132436","journal-title":"J Exp Med"},{"key":"BFncprheum0139_CR53","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/01.ASN.0000048716.42876.14","volume":"14","author":"R Birck","year":"2003","unstructured":"Birck R et al. (2003) 15-deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14: 440\u2013447","journal-title":"J Am Soc Nephrol"},{"key":"BFncprheum0139_CR54","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfh763","volume":"20","author":"WH Schmitt","year":"2005","unstructured":"Schmitt WH et al. (2005) Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 20: 1083\u20131092","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0139","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncprheum0139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:57:44Z","timestamp":1684443464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["BFncprheum0139"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0139","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}